|Systematic (IUPAC) name|
|AHFS/Drugs.com||Micromedex Detailed Consumer Information|
|ATC code||P01CB01 (WHO) QP51AB01 (WHO)|
|(what is this?)|
Meglumine antimoniate (or meglumine antimonate) is a medicine used for treating leishmaniasis. It is manufactured by Aventis and sold as Glucantime in France, and Glucantim in Italy. It belongs to a group of compounds known as the pentavalent antimonials. It is administered by intramuscular injection.
- Soto, J.; Fuya, P.; Herrera, R.; Berman, J. (1998). "Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: Controlled study". Clinical Infectious Diseases. 26 (1): 56–58. doi:10.1086/516267. PMID 9455509.
- Aventis press release, 15 April 2005. (German)
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|